Jay T. Backstrom

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · Journal of Clinical Oncology · 2009 · 958 citations · Full text

Medicine, Oncology, Pharmacology +13

Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2006 · 553 citations

Medicine, Pharmacology, Pharmacotherapy +13

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

Roger M. Lyons, Thomas M. Cosgriff, Sanjiv Modi et al. · Journal of Clinical Oncology · 2009 · 272 citations

Medicine, Pharmacology, Pharmacotherapy +17

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

Leonie Saft, Masoud Karimi, Mehran Ghaderi et al. · Haematologica · 2014 · 136 citations · Full text

Medicine, Hematology, Oncology +17